Osteoporosis Drugs Market to Witness Healthy Growth in Coming Years
Rising prevalence of
osteoporosis and surge in geriatric population to drive global osteoporosis
drugs market
According to
TechSci Research report, “Global Osteoporosis
Drugs Market By Drug Class (Bisphosphonates, Selective Estrogen Inhibitors
Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand
Inhibitors, and Others), By Route of Administration (Oral, Injectable, and
Others), By Region, Forecast & Opportunities, 2025”, the market is anticipated to grow at a healthy CAGR during
the forecast period. The key factors propelling the growth of global
osteoporosis drugs market include rising prevalence of osteoporosis and surge
in geriatric population around the world as they pose high susceptibility for
osteoporosis. Growing adoption of sedentary lifestyle is also impacting bone
health and thus, there is a rise in demand for osteoporosis drugs. In addition,
increase in osteoporosis cases due to menopause in women is acting as a major
growth driver for this market. In men, lifestyle associated factors such as smoking,
and alcohol abuse are found to promote osteoporosis. This is further expected
to augment the global osteoporosis drugs market through 2025.
Moreover, increasing investment in R&D activities
for development of advanced new drug classes are also fueling the market
growth. The wide range of pipeline drugs for approval in clinical trials are
also expected to provide lucrative growth opportunity for osteoporosis drug
manufacturers. However, the market is also prone to some challenges. Several
side effects of osteoporosis drugs such as heartburn, nausea, irritable bowel
syndrome and ulcers in the stomach are likely to hamper the market growth.
Furthermore, the time-taking drug approval process is also anticipated to
restrain the global osteoporosis drugs market growth.
Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on "Global Osteoporosis
Drugs Market"
https://www.techsciresearch.com/report/osteoporosis-drugs-market/5081.html
The global osteoporosis
drugs market is segmented based on drug class, route of administration and
region. Based on drug class, the market can be segmented into bisphosphonates,
Selective Estrogen Inhibitors Modulator (SERM), parathyroid hormone therapy,
calcitonin, rank ligand inhibitors, and others. Among them, rank ligand inhibitors
are expected to register highest CAGR during the forecast period as they are increasingly being used to treat bone metastasis.
They work by acting as a chemoattractant to bone for tumour cells that express
its receptor, RANK.
Based on route of administration, global osteoporosis
drugs market can be segmented into oral, injectable, and others. Among them, the
oral segment accounted for largest market share in 2019 owing to abundant
availability of medications which are taken orally. However, the injectable
segment is anticipated to witness fastest growth through 2025 owing to growing
need for drugs that exhibit improved bioavailability rapid mode of action.
Major players operating in the global
osteoporosis drugs market include F. Hoffmann-La Roche Ltd, Pfizer, Inc., Teva
Pharmaceuticals Industries Ltd., Novartis International AG, GlaxoSmithKline
Plc, Merck & Co. Inc., Amgen, Inc., Allergan plc, Eli Lilly and Company,
Radius Health, Inc., Sun Pharmaceutical Industries Ltd. and Takeda
Pharmaceutical Company Limited. The companies are undergoing new product
development and collaborative research initiatives to increase their share in
global osteoporosis drugs market
Download
Sample Report
@
https://www.techsciresearch.com/sample-report.aspx?cid=5081
Customers can
also request for 10% free customization on this report.
“North America
dominated the global osteoporosis drugs market in 2019 and is expected to hold
its dominance through 2025 owing to rising prevalence of osteoporosis and easy
availability of osteoporosis drugs in the region. However, Asia Pacific is
anticipated to undergo fastest growth during the forecast period due to
thriving life science industry and growing awareness about the benefits of osteoporosis
drugs,” said Mr. Karan Chechi, Research Director with TechSci Research, a
research based global management consulting firm.
“Global Osteoporosis Drugs Market By Drug
Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM),
Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, and Others),
By Route of Administration (Oral, Injectable, and Others), By Region, Forecast
& Opportunities, 2025” has evaluated
the future growth potential of global osteoporosis drugs market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges and opportunities in global osteoporosis drugs market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]